New Drug Approvals

APRIL 19, 2025

“Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias” Clinical Pharmacology and Therapeutics. . ^ Jump up to: a b c d [link] ^ “List of nationally authorised medicinal products Active substance: landiolol” (PDF). Procedure no.: 22 (4): 3616.

FDA 62

FDA Clinical Trials Treatment Trials 62

Metabolite Tales Blog

JULY 5, 2023

However, more de novo designed molecules in this “beyond the Rule of 5 chemical space” have emerged, with the first in this class, plerixafor , approved in oncology in 2008. Still, of the 34 macrocycles currently in clinical trials, only 18% are de novo designed. link] [9] PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION.

Drugs 52

Drugs Metabolic Stability FDA Approval Treatment 52

Metabolite Tales Blog

JULY 5, 2023

2] However, more de novo designed molecules in this “beyond the Rule of 5 chemical space” have emerged, with the first in this class, plerixafor , approved in oncology in 2008. Still, of the 34 macrocycles currently in clinical trials, only 18% are de novo designed. link] [9] PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION.

Metabolic Stability 52

Metabolic Stability Drugs FDA Approval Treatment 52

Drug Target Review

NOVEMBER 27, 2024

2008 Aug 1;63(8):879–84. Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020. Clinical Pharmacology & Therapeutics. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. Food and Drug Administration.

Drug Development 52

Drug Development Regulations Laboratories FDA 52